Amalgamated Bank Has $1.15 Million Position in LivaNova PLC (NASDAQ:LIVN)

Amalgamated Bank increased its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 3.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 24,900 shares of the company’s stock after buying an additional 729 shares during the quarter. Amalgamated Bank’s holdings in LivaNova were worth $1,153,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in LIVN. Central Pacific Bank Trust Division increased its holdings in shares of LivaNova by 21.2% during the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock worth $191,000 after buying an additional 720 shares in the last quarter. Captrust Financial Advisors bought a new stake in LivaNova during the 3rd quarter worth $217,000. Sanctuary Advisors LLC acquired a new position in LivaNova in the 3rd quarter worth about $219,000. Edgestream Partners L.P. acquired a new position in shares of LivaNova in the third quarter valued at approximately $244,000. Finally, GSA Capital Partners LLP bought a new position in LivaNova in the 3rd quarter valued at approximately $292,000. Institutional investors own 97.64% of the company’s stock.

Insider Transactions at LivaNova

In related news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the transaction, the director now owns 7,522 shares in the company, valued at $383,546.78. The trade was a 14.25 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.27% of the company’s stock.

LivaNova Trading Up 0.2 %

NASDAQ LIVN opened at $41.72 on Tuesday. The stock has a market capitalization of $2.27 billion, a P/E ratio of 99.33 and a beta of 1.00. The business has a 50 day simple moving average of $47.30 and a 200 day simple moving average of $49.52. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. LivaNova PLC has a one year low of $40.37 and a one year high of $64.47.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. StockNews.com cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 26th. Wolfe Research downgraded LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday, February 26th. Needham & Company LLC decreased their price target on LivaNova from $75.00 to $64.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Mizuho cut their price objective on LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 26th. Finally, Stifel Nicolaus decreased their target price on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $62.20.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.